… to the first-generation TKI erlotinib or gefitinib in the FLAURA study. In a post hoc analysis,
a … I BLOOM trial as upfront treatment (n = 41) and in a recent retrospective multi-center study …

… The present multicenter study … erlotinib plus VEGF inhibitors and gefitinib plus cytotoxic
agents, compared with first-generation EGFR-TKI monotherapy. The NEJ026 trial, a phase 3 trial, …

… trial to date, which compares gefitinib and erlotinib treatment, not to mention a study
performed based on the tumor EGFR mutation status. In the present study, we retrospectively …

… study indicated that erlotinib, gefitinib, afatinib and icotinib shared equivalent efficacy but
presented different efficacy-toxicity pattern for EGFR-mutated patients. Erlotinib … retrospective …

… in gefitinib and erlotinib studies, the PFS and OS in this study … However, one should note
that this is a retrospective study … the abovementioned studies on gefitinib and erlotinib were all …

… This retrospective population-based study included patients with NSCLC who received first-line
afatinib, gefitinib, or erlotinib … are known to be resistant to afatinib, gefitinib, and erlotinib. …

… We analyzed retrospectively 575 NSCLC patients treated with gefitinib to identify … gefitinib
therapy but also to conduct future prospective clinical studies, including translational studies …

… mixed) and to trial design (retrospective versus prospective EGFR analysis), was found; a
trend toward significance with regard to type of drug (gefitinib versus erlotinib versus afatinib) …

… MST compared with gefitinib and icotinib (P<0.05). In conclusion, gefitinib, erlotinib and
icotinib … However, gefitinib resulted in a lower frequency of fatigue, and nausea and vomiting, …

… We conducted a multicenter retrospective study across three medical centers in Japan.
The study design and methodology was approved by the Institutional Review Board of each …